GnRH agonists are used in premenopausal breast cancer and allow ovarian conservation, although the use of GnRH agonists sequentially or concurrently with chemotherapy shows no significant difference in all-cause survival [16, 17]. This evidence concerns the gene GNRH1 and breast cancer.